Dawn L. Sammons, DO, FAOCD, FAAD

Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.

Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.

Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.

Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.

Experts in dermatology review a patient case of a 48-year-old man with plaque psoriasis who is having trouble with topical therapy.

Dermatology experts discuss a patient case concerning a 60-year-old woman with chronic intertriginous psoriasis who is taking a biologic drug for inflammatory bowel disease.

Dawn L. Sammons, DO, FAOCD, FAAD, and Benjamin Lockshin, MD, FAAD, review a case of a female patient with a family history of plaque psoriasis.

Experts discuss the unique mechanism of action of tapinarof and its use in the treatment of plaque psoriasis.

James Q. Del Rosso, DO, and Dawn L. Sammons, DO, FAOCD, FAAD, review the efficacy of a new topical agent in the treatment of plaque psoriasis, tapinarof, highlighting the remittive data.

Experts in dermatology discuss newer topical treatments, such as tapinarof, in the management of plaque psoriasis.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.

Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.